La bourse est fermée

Ipsen S.A. (IPN.PA)

Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
120,50-2,60 (-2,11 %)
À la clôture : 05:35PM CEST

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Secteur(s)Healthcare
Secteur d’activitéDrug Manufacturers - Specialty & Generic
Employés à temps plein5 325

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. David LoewMD, CEO & Director2,11MS.O.1967
Mr. Aymeric Le ChatelierExecutive VP & CFO731,25kS.O.1969
Dr. Aidan Murphy Ph.D.Executive VP and Head of Technical OperationsS.O.S.O.1966
Mr. Craig MarksVice-President of Investor RelationsS.O.S.O.S.O.
Mr. Francois GarnierExecutive VP of Legal Affairs, General Counsel & Chief Business Ethics OfficerS.O.S.O.1962
Ms. Gwenan WhiteExecutive VP and Head of Communications, Public Affairs & SustainabilityS.O.S.O.S.O.
Mr. Regis MulotExecutive VP & Chief Human Resources OfficerS.O.S.O.1966
Ms. Dominique BeryHead of Nordics & BalticsS.O.S.O.1971
Mr. Bartosz Bednarz D.D.S.Executive VP and Head of Global Product & Portfolio StrategyS.O.S.O.S.O.
Mr. Philippe Lopes-Fernandes CBOExecutive VP & Chief Business OfficerS.O.S.O.S.O.
Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en EUR.

Description

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Ipsen S.A. en date du 1 juin 2024 est 8. Les scores principaux sont Audit : 8; Société : 8; Droits des actionnaires : 7; Compensation : 7.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.